Leading the charge

Led by a mission-driven team, Innoviva Specialty Therapeutics blends rigorous medical science with the latest in pharmaceutical innovation

Executive Team

Pavel Raifeld, CFA

Chief Executive Officer

Pavel brings deep financial and strategic expertise from experiences at Sarissa Capital Management, Credit Suisse’s healthcare investment banking, and biopharmaceutical consulting at McKinsey & Company and BCG. He holds a BA from Harvard and an MBA from Columbia University.

Marianne Zhen

Chief Accounting Officer

Joining Innoviva in 2014, Marianne previously served as Corporate Controller for three tech companies. A member of the AICPA and the CalCPA, she also served on the CalCPA Peninsula Silicon Valley Chapter board. Marianne holds a BS in Business Administration from San Francisco State University.

Matt Ronsheim, PhD

Chief Technology Officer

Dr. Ronsheim has led teams in development, CMC, and supply chain across various formulations and disease areas at Enanta Pharmaceuticals, Merck/Cubist, and Forest Laboratories. He holds a BS from Southern Connecticut State University and a PhD in Synthetic Organic Chemistry from the University of New Hampshire.

David Altarac, MD, MPA

Chief Medical Officer

Dr. Altarac was SVP at Shire, VP at NeoStem, and held senior leadership positions at Merck. As clinician and scientist, he has authored numerous scientific publications and led medical research in multiple organizations. He holds a BA in Chemistry from SUNY, an MPA from NYU, and an MD from New York Medical College.

Christine Coyne

Chief Commercial Officer

Before joining Innoviva, Christine was CCO at SCYNEXIS and held leadership roles at Paratek. She has also led marketing and sales teams at Wyeth-Ayerst Global Pharmaceuticals, Endo, and Auxilium Pharmaceuticals. She holds a BA from West Chester University and an MBA from Eastern University.


Join a team where all colleagues can do their best work while making a lasting impact.

Learn More